ADR

DADA NEXUS LIMITED (NASDAQ: DADA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Dada Nexus Limited

Retrieved on: 
Monday, March 4, 2024
Nexus, Court, Marketing, News, ADR, Advertising, Complaint, District court, Form 6-K, Security (finance)

NEW YORK, March 04, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Key Points: 
  • NEW YORK, March 04, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
    Do you, or did you, own shares of Dada Nexus Limited (NASDAQ: DADA)?
  • Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Dada Nexus Limited (“Dada” or the “Company”) (NASDAQ: DADA) between May 11, 2023 and January 8, 2024, inclusive (the “Class Period”).
  • If you wish to serve as lead plaintiff, you must move the Court no later than March 11, 2024.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

GRFS Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Grifols S.A. (NASDAQ: GRFS) Investors with Significant Losses to Contact the Firm

Retrieved on: 
Friday, March 1, 2024
LLP, ADR, News, American depositary receipt, Government

RADNOR, Pa., March 01, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities laws on behalf of investors of Grifols S.A. (NASDAQ: GRFS) (“Grifols”).

Key Points: 
  • RADNOR, Pa., March 01, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities laws on behalf of investors of Grifols S.A. (NASDAQ: GRFS) (“Grifols”).
  • If you are a Grifols investor and would like to learn more about our investigation, please CLICK HERE to fill out our online form or contact Kessler Topaz Meltzer & Check, LLP : Jonathan Naji, Esq.
  • For more information about Kessler Topaz Meltzer & Check, LLP , please visit www.ktmc.com .
  • Kessler Topaz Meltzer & Check, LLP

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Hywin Holdings Ltd. Investors to Inquire About Securities Class Action Investigation – HYW

Retrieved on: 
Friday, March 1, 2024
Titan, News, ADR, HYW, Advertising, Failure

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=21975 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against British American Tobacco p.l.c. - BTI 

Retrieved on: 
Wednesday, February 28, 2024
BAT, Pomerantz, Court, Reynolds American, Prior, News, ADR, Complaint, Ext, American Tobacco Company, British American Tobacco, Smokeless, Natural American Spirit, Action Replay

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against British American Tobacco p.l.c.

Key Points: 
  • NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against British American Tobacco p.l.c.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • The class action concerns whether BAT and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of HSBC Holdings plc - HSBC

Retrieved on: 
Wednesday, February 28, 2024
Pomerantz, HSBC, Prior, Bank, ADR, News, Sale

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HSBC Holdings plc (“HSBC” or the “Company”) (NYSE: HSBC).

Key Points: 
  • NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HSBC Holdings plc (“HSBC” or the “Company”) (NYSE: HSBC).
  • The investigation concerns whether HSBC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sibanye Stillwater Limited - SBSW

Retrieved on: 
Wednesday, February 28, 2024
Pomerantz, Prior, News, ADR

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sibanye Stillwater Limited (“Sibanye” or the “Company”) (NYSE: SBSW).

Key Points: 
  • NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sibanye Stillwater Limited (“Sibanye” or the “Company”) (NYSE: SBSW).
  • The investigation concerns whether Sibanye and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • On February 21, 2024, Sibanye issued a press release providing a “production update and trading statement” for 2023.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Dada Nexus Limited - DADA

Retrieved on: 
Wednesday, February 28, 2024
Nexus, Pomerantz, Exchange, Court, Dada, The Independent Review, Marketing, News, ADR, Complaint, Advertising, Ext, Action Replay

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Dada Nexus Limited (“Dada” or the “Company”) (NASDAQ: DADA).

Key Points: 
  • NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Dada Nexus Limited (“Dada” or the “Company”) (NASDAQ: DADA).
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • The class action concerns whether Dada and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

BRITISH AMERICAN TOBACCO P.L.C. (NYSE: BTI) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against British American Tobacco p.l.c.

Retrieved on: 
Monday, February 26, 2024
BAT, Court, Reynolds American, Action Replay, News, ADR, Advertising, Complaint, District court, BTI, American Tobacco Company, Natural American Spirit, Tobacco

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Key Points: 
  • NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
    Do you, or did you, own shares of British American Tobacco p.l.c.
  • Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of British American Tobacco p.l.c.
  • If you purchased or acquired BAT securities, and/or would like to discuss your legal rights and options please visit British American Tobacco p.l.c.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

DADA NEXUS LIMITED (NASDAQ: DADA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Dada Nexus Limited

Retrieved on: 
Monday, February 26, 2024
Nexus, Court, Marketing, News, ADR, Advertising, Complaint, District court, Form 6-K, Security (finance)

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Key Points: 
  • NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
    Do you, or did you, own shares of Dada Nexus Limited (NASDAQ: DADA)?
  • Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Dada Nexus Limited (“Dada” or the “Company”) (NASDAQ: DADA) between May 11, 2023 and January 8, 2024, inclusive (the “Class Period”).
  • If you wish to serve as lead plaintiff, you must move the Court no later than March 11, 2024.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Retrieved on: 
Monday, February 26, 2024
Neoplasm, Regenerative medicine, CIRM, B-cell lymphoma, Graft-versus-host disease, Investment, TRAC, ADR, CD19, Cytokine release syndrome, Cell, Destiny, HER2, BCMA, Lupus, IPSC, Safety, GAAP, Therapy, Trastuzumab, Pharmacokinetics, Lymphoid leukemia, Patient, NK, Multiple myeloma, SLE, Immunotherapy, Research, CRS, Vaccine

SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Total Operating Expenses: For the fourth quarter of 2023, GAAP operating expenses were $49.8 million, including research and development expenses of $31.8 million and general and administrative expenses of $17.9 million.
  • Shares Outstanding: Common shares outstanding were 98.6 million, and preferred shares outstanding were 2.8 million, as of December 31, 2023.
  • ET to review financial and operating results for the quarter and full year ended December 31, 2023.
  • The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.fatetherapeutics.com.